<div class="white-sheet">
	<div class="content-slide">

		<div class="title-bar red"></div>

		<div class="wrapper slide-2-6-2-7">

			<div class="popups" style="position:absolute">
				<div data-effect="fade" data-duration="1000" data-target="references-overlay" data-width="600" data-height="490" class="references-button show-overlay"></div>
				<div data-effect="fade" data-duration="1000" data-target="information-overlay" data-width="600" data-height="490" class="information-button show-overlay"></div>		
			</div>

			<div class="slide-title red">
				Supportive care in severe aplastic anaemia: burden of treatment
			</div>


			<div class="content-container">

				<ul>
					<li><span>Although transplant options must be pursued in the event of persistent pancytopenia despite IST, supportive care strategies may still have to be used<sup>1</sup></span></li>
					<li><span>Transfusions may be implemented to correct anaemia and thrombocytopenia<sup>1</sup></span>
						<ul>
							<li><span>However, repeated red blood cell transfusions can lead to iron overload, causing significant damage to internal organs and increasing mortality risk<sup>2</sup></span></li>
						</ul>
					</li>
					<li><span>Broad-spectrum parenteral antibiotics may be required when fever or documented infection occurs in the presence of severe neutropenia<sup>1</sup></span>
						<ul>
							<li><span>G-CSF may be used to stimulate a neutrophil response in the event of severe infection<sup>3</sup></span></li>
						</ul>
					</li>
					<li><span>Growth factors, including G-CSF and EPO, may be used to support blood counts, although evidence does not suggest that they improve relapse rates or survival<sup>3â€“5</sup></span></li>
				</ul>

			</div>

		</div>

		<div class="information-overlay overlay">
			
			<header>Supportive care in severe aplastic anaemia: burden of treatment</header>

			<ul>
				<li><span>Although transfusions may be used to correct anaemia and thrombocytopenia, post-transfusion complications may occur, including:</span>
					<ul>
						<li><span>Acute haemolytic transfusion reaction in the event of blood type (ABO) incompatibility<sup>6,7</sup></span>
							<ul>
								<li><span>Symptoms include fever, hypotension and/or dyspnoea within minutes to hours of a transfusion<sup>6</sup></span></li>
								<li><span>Reactions may also occur up to 28 days after a transfusion<sup>6</sup></span></li>
								<li><span>Anaphylaxis<sup>6,8</sup></span>
									<ul>
										<li><span>An important cause of transfusion-related morbidity<sup>6</sup></span></li>
										<li><span>Most allergic and anaphylactic reactions are due to platelet-derived microparticles<sup>8</sup></span></li>
									</ul>
								</li>
								<li><span>Development of antibodies against blood cell antigens (including human leukocyte [HLA] and platelet [HPA] antigens), also known as alloimmunisation, may occur following regular blood product transfusions (particularly platelets)<sup>6,7</sup></span>
									<ul>
										<li><span>Anti-HPA antibody development may result in refractivity to donor platelet transfusions,<sup>6</sup> rendering an important supportive strategy ineffective</span></li>
									</ul>
								</li>
							</ul>
						</li>
					</ul>
				</li>
			</ul>

		</div>


		<div class="references-overlay overlay">

			<header>References</header>
				
			<ol>
				<li class="navigateHref" data-navtarget="media/documents/module2/ScheinbergP-2012-Blood-v120p1185.pdf"><span>Scheinberg P <i>et al. Blood</i> 2012;120:1185</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/LeeJW-2010-Blood-v116p2448.pdf"><span>Lee JW <i>et al. Blood</i> 2010;116:2448</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/MarshJ-2009-BrJHaematol-v147p43.pdf"><span>Marsh JCW <i>et al. Br J Haematol</i> 2009;147:43</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/GurionR-2009-Haematologica-v94p712.pdf"><span>Gurion R <i>et al. Haematologica</i> 2009;94:712</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/DeZernA-2011-ExpertRevHematol-v4p221.pdf"><span>De Zern A & Brodsky RA. <i>Expert Rev Hematol</i> 2011;4:221</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/DutchBloodTransfusionGuidelines-2011.pdf"><span>Dutch Blood Transfusion Guideline. 2011. http://www.sanquin.nl/repository/documenten/en/prod-en-dienst/287294/blood-transfusion-guideline.pdf (accessed January 2014)</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/AnnualSHOTReport-2011.pdf"><span>Annual SHOT report. Serious Hazards of Transfusion steering group. 2011. http://www.shotuk.org/wp-content/uploads/2012/07/SHOT-ANNUAL-REPORT_FinalWebVersionBookmarked_2012_06_22.pdf (accessed January 2014)</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/GilstadC-2003-CurrOpinHematol-v10p419.pdf"><span>Gilstad CW. <i>Curr Opin Hematol</i> 2003;10:419</span></li>
			</ol>
		</div>

	</div>
</div>